Literature DB >> 18277925

Risk factors for meningococcal disease in students in grades 9-12.

Lee H Harrison1, Carolyn J Kreiner, Kathleen A Shutt, Nancy E Messonnier, Mary O'Leary, Karen R Stefonek, Huai Lin, Ruth Lynfield, Nancy L Barrett, Kathryn E Arnold, Timothy F Jones, José T Montero.   

Abstract

BACKGROUND: Meningococcal disease is a serious problem in adolescents, including high school students. Universal immunization of adolescents with meningococcal conjugate vaccine was recently recommended. We studied risk factors for meningococcal disease in students in grades 9-12.
METHODS: This was a matched case-control study using surveillance for meningococcal disease in students in grades 9-12 in sites throughout the United States. For each case-patient, up to 4 controls were selected from the home room classroom. All subjects answered an extensive questionnaire. Logistic regression was performed to identify risk factors associated with meningococcal disease. Meningococcal isolates were characterized.
RESULTS: Of 69 eligible patients, 49 (71%) were enrolled and had at least 1 control. Isolates were available for 59 (86%) cases. Attending at least 1 barbeque or picnic [matched odds ratio (MOR): 0.26, P value = 0.003] or school dance (MOR: 0.30, P = 0.04) were independently associated with decreased risk of meningococcal disease. Male gender (MOR: 2.94, P = 0.009), upper respiratory infection symptoms (MOR: 2.43, P = 0.04), marijuana use (MOR: 4.21, P = 0.009), and nightclub/disco attendance (MOR: 3.30, P = 0.04) were associated with increased risk. Among 54 students not from Oregon (where serogroup B strains predominate) with available serogroup, 38 (73.1%) cases were potentially vaccine preventable: 18 (34.6%) serogroup C, 19 (36.5%) serogroup Y, and 1 (1.9%) serogroup W-135.
CONCLUSIONS: Certain behaviors increase the risk of meningococcal infection, whereas others are associated with decreased risk. Most meningococcal disease in high school students can be prevented if recommendations on use of meningococcal conjugate vaccine are implemented.

Entities:  

Mesh:

Year:  2008        PMID: 18277925     DOI: 10.1097/INF.0b013e31815c1b3a

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  13 in total

1.  Meningococcal carriage among a university student population - United States, 2015.

Authors:  Lucy Breakwell; Melissa Whaley; Unab I Khan; Utpala Bandy; Nicole Alexander-Scott; Lynn Dupont; Cindy Vanner; How-Yi Chang; Jeni T Vuong; Stacey Martin; Jessica R MacNeil; Xin Wang; Sarah A Meyer
Journal:  Vaccine       Date:  2017-11-26       Impact factor: 3.641

Review 2.  Epidemiological profile of meningococcal disease in the United States.

Authors:  Lee H Harrison
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

3.  Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database.

Authors:  Muhamed-Kheir Taha; Catherine Weil-Olivier; Stéphane Bouée; Corinne Emery; Gaëlle Nachbaur; Céline Pribil; Véronique Loncle-Provot
Journal:  Hum Vaccin Immunother       Date:  2021-01-15       Impact factor: 3.452

4.  Bacteraemic pneumonia caused by Neisseria meningitidis serogroup Y.

Authors:  Maria Pilar Romero-Gomez; Zaida Rentero; Jose Ramon Paño; Jesus Mingorance
Journal:  Respir Med Case Rep       Date:  2011-12-26

Review 5.  Routinely vaccinating adolescents against meningococcus: targeting transmission & disease.

Authors:  Volker Vetter; Roger Baxter; Gülhan Denizer; Marco A P Sáfadi; Sven-Arne Silfverdal; Andrew Vyse; Ray Borrow
Journal:  Expert Rev Vaccines       Date:  2016-03-04       Impact factor: 5.217

6.  A Case-Control Study on the Risk Factors for Meningococcal Disease among Children in Greece.

Authors:  Christos Hadjichristodoulou; George Mpalaouras; Vasiliki Vasilopoulou; Antonios Katsioulis; George Rachiotis; Kalliopi Theodoridou; Georgia Tzanakaki; Vassiliki Syriopoulou; Maria Theodoridou
Journal:  PLoS One       Date:  2016-06-28       Impact factor: 3.240

7.  Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.

Authors:  Beatriz P Quiambao; Hermant Jain; Ashish Bavdekar; Anand Prakash Dubey; Devayani Kolhe; Véronique Bianco; Marie Van der Wielen; Jacqueline M Miller
Journal:  Hum Vaccin Immunother       Date:  2016-05-06       Impact factor: 3.452

8.  Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.

Authors:  Beatriz P Quiambao; Ashish Bavdekar; Anand Prakash Dubey; Hemant Jain; Devayani Kolhe; Véronique Bianco; Jacqueline M Miller; Marie Van der Wielen
Journal:  Hum Vaccin Immunother       Date:  2017-02-02       Impact factor: 3.452

Review 9.  Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States.

Authors:  Angelika Banzhoff
Journal:  Ther Adv Vaccines       Date:  2017-01-06

10.  Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review.

Authors:  Femke van Kessel; Caroline van den Ende; Anouk M Oordt-Speets; Moe H Kyaw
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.